Patent No. EP3475417 (titled "Compositions And Methods For Making Benzylisoquinoline Alkaloids, Morphinan Alkaloids, Thebaine, And Derivatives Thereof") was filed by Antheia on Jun 27, 2017. The application was issued on May 24, 2023.
This invention provides a genetically modified cell—specifically a bacterium, yeast, or fungus—comprising a polynucleotide encoding a thebaine synthesis polypeptide. This enzyme converts salutaridinol-7-O-acetate to thebaine, accelerating a reaction typically considered spontaneous and thermodynamically unfavorable. The polypeptide comprises an amino acid sequence with at least 70% identity to SEQ ID NO. 6, 31, or 32. The invention further encompasses the in vitro use of these polypeptides, vectors for host cell expression, and methods for producing thebaine by growing the modified cells in a base substrate medium. Additionally, the system may include a purine permease to increase thebaine titers. Thebaine produced via this method can be further converted into various morphinan alkaloid derivatives, such as morphine, codeine, and oxycodone.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description